HepCare Europe 项目 HepCheck:强化社区外展筛查提升脆弱人群 HCV 发现与转诊
HepCheck 在欧洲四国社区成瘾、无家可归者及监狱服务机构开展前瞻性多中心可行性研究,对 2822 人提供 HCV 抗体与 RNA 检测、肝纤维化评估及专科转诊。筛查接受率 74%(n=2079),发现 397 例(19%)活动性 HCV 感染,其中 136 例为新病例,80% 的活动性感染者成功转诊至专科服务。
要点
- 社区外展筛查在高风险人群中 HCV 筛查接受率达 74%。
- 共发现 397 例活动性 HCV 感染,其中 136 例为新诊断病例。
- 80% 的活动性感染者成功转诊至专科服务并接受肝纤维化评估。
核心结论
- HepCheck 的筛查与转诊策略可有效覆盖包括未接触任何社区照护的最高传播风险人群在内的脆弱群体。
- EU 仅能通过此类以患者为中心的创新方法实现 HCV 消除。
研究设计与样本
- 前瞻性多中心可行性研究,研究团队来自四个欧洲国家。
- 在社区成瘾、无家可归者和监狱服务机构中开展筛查,共向 2822 人提供筛查。
- 筛查内容包括自填问卷、HCV 抗体与 RNA 检测、肝纤维化评估及转诊至专科服务。
主要发现
- 筛查接受率为 74%(n=2079)。
- 样本中男性占 85.8%(n=1783),44.6%(n=927)曾注射毒品,38.4%(n=799)曾无家可归,27.9%(n=581)为囚犯。
- 共发现 397 例(19%)活动性 HCV 感染,其中 136 例(占总样本 7%,占活动性感染的 34%)为新病例。
- 在活动性 HCV 感染者中,80% 被转诊至专科服务,包括肝纤维化评估和专科转诊。
临床怎么用
- 在社区成瘾、无家可归者和监狱服务等机构中开展强化外展筛查,可提高脆弱人群 HCV 感染发现率。
- 筛查应整合 HCV 抗体与 RNA 检测、肝纤维化评估及直接转诊至专科服务,以促进照护衔接。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hepatitis C is one of the main causes of chronic liver diseases worldwide. One of the major barriers to effecting EU- and WHO-mandated HCV elimination by 2030 is underdiagnosis. Community-based screening strategies have been identified as important components of HCV models of care. HepCheck Europe is a large-scale intensified screening initiative aimed at enhancing identification of HCV infection among vulnerable populations and linkage to care. METHODS: Research teams across four European countries were engaged in the study and rolled out screening to high-risk populations in community addiction, homeless and prison services. Screening was offered to 2822 individuals and included a self-administered questionnaire, HCV antibody and RNA testing, liver fibrosis assessment and referral to specialist services. RESULTS: There was a 74% (n=2079) uptake of screening. The majority (85.8%, n=1783) were male. In total 44.6% (n=927) of the sample reported ever injecting drugs, 38.4% (n=799) reported ever being homeless and 27.9% (n=581) were prisoners. In total 397 (19%) active HCV infections were identified and 136 (7% of total sample and 34% of identified active infections) were new cases. Of those identified with active HCV infection, 80% were linked to care, which included liver fibrosis assessment and referral to specialist services. CONCLUSIONS: HepCheck's screening and linkage to care is a clear strategy for reaching high-risk populations, including those at highest risk of transmission who are not accessing any type of care in the community. Elimination of HCV in the EU will only be achieved by such innovative, patient-centred approaches.
引用
- Barror S, Avramovic G, Oprea C, et al. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother. 2019. PMID: 31782499. doi:10.1093/jac/dkz455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。